Work

Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT).

Year: 2010

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2010.28.18_suppl.lba7523

Authors: M. J. Boyer, F. H. Blackhall, K. Park, C. H. Barrios, M. J. Krzakowski, I. Taylor, J. Q. Liang, L. J. Denis, J. P. O'Connell, S. S. Ramalingam

Institutions: Samsung Medical Center, The Christie NHS Foundation Trust, Hospital São Lucas da PUCRS, Winship Cancer Institute, Sungkyunkwan University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2243008132

Cites:

Cited by: 51

Related to: 10